Research Analysts’ Recent Ratings Changes for Sutro Biopharma (STRO)

A number of research firms have changed their ratings and price targets for Sutro Biopharma (NASDAQ: STRO):

• 11/4/2026 – Sutro Biopharma was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/31/2026 – Sutro Biopharma was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 10/19/2026 – Sutro Biopharma was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/16/2026 – Sutro Biopharma had its “buy” rating reaffirmed by HC Wainwright.
• 10/15/2026 – Sutro Biopharma had its “outperform” rating reaffirmed by Wedbush. They now have a $60.00 price target on the stock.
• 9/30/2026 – Sutro Biopharma is now covered by Wells Fargo & Company. They set an “overweight” rating and a $49.00 price target on the stock.
• 9/19/2026 – Sutro Biopharma was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/16/2026 – Sutro Biopharma was upgraded by Mizuho to “strong-buy”.
• 9/7/2026 – Sutro Biopharma was upgraded by Mizuho to “strong-buy”.

Sutro Biopharma Stock Up 5.3%

NASDAQ STRO traded up $0.49 on Friday, reaching $9.69. The stock had a trading volume of 35,646 shares, compared to its average volume of 272,065. The firm has a market capitalization of $160.64 million, a price-to-earnings ratio of -0.81 and a beta of 1.56. Sutro Biopharma, Inc. has a 12-month low of $7.15 and a 12-month high of $43.85. The stock has a fifty day moving average price of $14.45 and a two-hundred day moving average price of $22.71.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.19) by ($0.14). The business had revenue of $9.84 million for the quarter, compared to the consensus estimate of $11.96 million. Sell-side analysts forecast that Sutro Biopharma, Inc. will post -8.12 earnings per share for the current fiscal year.

Sutro Biopharma, Inc is a clinical-stage biotechnology company focused on developing medicines for cancer and other serious diseases. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture targeted biologic therapies, including antibody-drug conjugates (ADCs) and cancer immunotherapies.

Sutro’s research programs have included luveltamab tazevibulin, also known as STRO-002, a folate receptor alpha-targeted ADC being investigated for ovarian and endometrial cancers.